ClinConnect ClinConnect Logo
Search / Trial NCT05097274

The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Oct 15, 2021

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Fch Pet Ct Psma Pet Ct

ClinConnect Summary

The GENPET Study is a clinical trial designed to see how effective a specific type of imaging, called FCH-PET-CT, is for detecting prostate cancer that has spread beyond the pelvis in men who have certain genetic mutations. These mutations affect how the body repairs DNA and include conditions like BRCA1 and BRCA2 mutations. Researchers want to find out if this new imaging method is better than the current standard tests, which use a combination of bone scans and MRI or CT scans of the abdomen and pelvis.

To participate in the study, men must be over 18 years old, have a confirmed genetic mutation related to DNA repair, and have been diagnosed with prostate cancer. They should be at a point in their treatment where imaging is needed, such as when they are first diagnosed or if they are experiencing a return of cancer after previous treatment. Participants will undergo the new imaging test and may have to meet certain health criteria to be eligible. It’s important to know that those with other types of cancer or significant health issues may not qualify. This study aims to improve how doctors detect and treat prostate cancer for men with these specific genetic concerns.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Confirmed pathogenic germline mutation in any of the following genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2 or ATM.
  • Over the age of 18
  • * Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either:
  • At a new diagnosis
  • Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy
  • Patients on active surveillance with a PSA doubling time of 6 months or less
  • Exclusion Criteria:
  • Diagnosis of other malignancy (excluding basal cell cancer/squamous cell cancer of the skin) within five years of diagnosis
  • Known metastatic prostate cancer, both local and distant
  • Patients who have received any oncological treatment within the last six months
  • Patients on any investigational drug treatment
  • Patients on steroids
  • Known history of inflammatory/infective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease)
  • Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers, aneurysm clips, claustrophobia)

About Institute Of Cancer Research, United Kingdom

The Institute of Cancer Research (ICR) in the United Kingdom is a leading cancer research organization dedicated to understanding the biology of cancer and developing innovative therapeutic strategies. Renowned for its pioneering contributions to cancer treatment and prevention, the ICR conducts cutting-edge clinical trials that translate laboratory discoveries into effective clinical applications. Collaborating with a network of academic, clinical, and industry partners, the ICR is committed to advancing cancer research and improving patient outcomes through rigorous scientific inquiry and a patient-centered approach.

Locations

London, Sutton, Surrey, United Kingdom

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Rosalind A Eeles, FRCP FRCR

Principal Investigator

Institute of Cancer Research and Royal Marsden Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials